Published in N Engl J Med on October 10, 1996
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data. Stat Sci (2005) 3.90
Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med (2008) 3.83
Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics (2008) 3.04
Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis (2012) 2.51
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials (2008) 1.99
Therapy for human immunodeficiency virus infection -- what have we learned? N Engl J Med (1996) 1.88
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis (2012) 1.86
Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes. Biostatistics (2003) 1.76
Variable selection for optimal treatment decision. Stat Methods Med Res (2011) 1.61
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother (1998) 1.60
Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. CMAJ (1998) 1.59
Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother (2002) 1.49
HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis (2012) 1.47
Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol (1997) 1.44
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol (2006) 1.32
Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1997) 1.28
Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents. J Med Chem (2009) 1.26
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
Improved doubly robust estimation when data are monotonely coarsened, with application to longitudinal studies with dropout. Biometrics (2010) 1.23
Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapy. J Gen Intern Med (1997) 1.22
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ (2002) 1.21
In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother (2003) 1.14
Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy. Dig Dis Sci (2005) 1.12
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci (2007) 1.07
British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). Sex Transm Infect (1999) 1.05
Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. J Med Chem (2010) 1.04
HIV entry inhibitors and their potential in HIV therapy. Med Res Rev (2009) 1.04
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One (2011) 1.04
Fast FSR variable selection with applications to clinical trials. Biometrics (2008) 1.01
Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. J Med Chem (2012) 1.00
Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J Virol (2000) 0.99
Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother (2000) 0.98
Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users. HIV Med (2012) 0.98
Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure. Clin Exp Immunol (2002) 0.97
'Smooth' inference for survival functions with arbitrarily censored data. Stat Med (2008) 0.97
Sufficient dimension reduction via bayesian mixture modeling. Biometrics (2010) 0.95
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
Semiparametric dimension reduction estimation for mean response with missing data. Biometrika (2010) 0.94
3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J Virol (1998) 0.92
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection. Proc Natl Acad Sci U S A (2001) 0.91
Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J Clin Microbiol (2004) 0.91
Monitoring patients with HIV disease. J Clin Pathol (2000) 0.91
Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol (2000) 0.90
Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child (2001) 0.90
Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor. J Virol (1998) 0.88
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. Antimicrob Agents Chemother (2000) 0.87
Regression survival analysis with an assumed copula for dependent censoring: a sensitivity analysis approach. Biometrics (2008) 0.87
Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother (2002) 0.87
Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. J R Soc Interface (2016) 0.85
Latent-model robustness in joint models for a primary endpoint and a longitudinal process. Biometrics (2009) 0.85
Impact of HAART on causes of death of persons with late-stage AIDS. J Urban Health (2000) 0.83
Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo. J Virol (2001) 0.83
Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One (2013) 0.83
Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials. Stat Med (2012) 0.83
Joint modeling of survival time and longitudinal data with subject-specific changepoints in the covariates. Stat Med (2010) 0.82
The evolution of HIV-1 group M genetic variability in Southern Cameroon is characterized by several emerging recombinant forms of CRF02_AG and viruses with drug resistance mutations. J Med Virol (2013) 0.82
Bootstrap for the case-cohort design. Biometrika (2014) 0.82
Palliative care for HIV disease in the era of highly active antiretroviral therapy. J Urban Health (2000) 0.81
Early increase of CD4+ CD45RA+ and CD4+ CD95- cells with conserved repertoire induced by anti-retroviral therapy in HIV-infected patients. Clin Exp Immunol (1998) 0.81
On optimal treatment regimes selection for mean survival time. Stat Med (2014) 0.81
Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. PLoS One (2012) 0.81
Janus considers the HIV pandemic--harnessing recent advances to enhance AIDS prevention. Am J Public Health (1997) 0.81
Change-Plane Analysis for Subgroup Detection and Sample Size Calculation. J Am Stat Assoc (2017) 0.80
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest (1997) 0.79
Practical issues regarding the use of antiretroviral therapy for HIV infection. West J Med (1998) 0.79
Proportional Hazards Model with Covariate Measurement Error and Instrumental Variables. J Am Stat Assoc (2014) 0.78
Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Viruses (2013) 0.78
Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. Eur J Epidemiol (1998) 0.78
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. J Int AIDS Soc (2006) 0.78
Identifying predictive markers for personalized treatment selection. Biometrics (2016) 0.78
A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics (2015) 0.77
Empirical Likelihood-Based Estimation of the Treatment Effect in a Pretest-Posttest Study. J Am Stat Assoc (2008) 0.77
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors. PLoS One (2016) 0.77
Closing the door to human immunodeficiency virus. Protein Cell (2013) 0.77
Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review). Oncol Rep (2013) 0.76
High-affinity RNA Aptamers Against the HIV-1 Protease Inhibit Both In Vitro Protease Activity and Late Events of Viral Replication. Mol Ther Nucleic Acids (2015) 0.76
Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation. PLoS One (2016) 0.76
Instrument Assisted Regression for Errors in Variables Models with Binary Response. Scand Stat Theory Appl (2015) 0.75
Joint modeling of longitudinal and survival data with the Cox model and two-phase sampling. Lifetime Data Anal (2016) 0.75
Statistics in medicine: some considerations from a clinician's point of view. Postgrad Med J (1998) 0.75
Fast Censored Linear Regression. Scand Stat Theory Appl (2013) 0.75
Landmark estimation of survival and treatment effects in observational studies. Lifetime Data Anal (2016) 0.75
Additive amelioration of ALS by co-targeting independent pathogenic mechanisms. Ann Clin Transl Neurol (2017) 0.75
Antiretroviral therapy for human immunodeficiency virus infection in 1997. West J Med (1997) 0.75
Semiparametric estimation of treatment effect with time-lagged response in the presence of informative censoring. Lifetime Data Anal (2011) 0.75
Approximate nonparametric corrected-score method for joint modeling of survival and longitudinal data measured with error. Biom J (2011) 0.75
Disease management--constructing optimal NRTI-based combinations: past, present, and future. MedGenMed (2006) 0.75
Statistical Methods for Establishing Personalized Treatment Rules in Oncology. Biomed Res Int (2015) 0.75
Expected estimating equation using calibration data for generalized linear models with a mixture of Berkson and classical errors in covariates. Stat Med (2013) 0.75
Locally Efficient Semiparametric Estimators for Proportional Hazards Models with Measurement Error. Scand Stat Theory Appl (2015) 0.75
Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol (1998) 0.75
HIV clinical trials are not enough. CMAJ (1999) 0.75
Semiparametric analysis of linear transformation models with covariate measurement errors. Biometrics (2013) 0.75
Pathogenesis and treatment of human immunodeficiency virus lipodystrophy. Indian J Endocrinol Metab (2012) 0.75
Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for. Genitourin Med (1997) 0.75
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med (1987) 8.64
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 6.38
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med (2001) 5.76
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med (1993) 4.43
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Macrophages and age-dependent resistance to Herpes simplex virus in mice. J Immunol (1970) 4.15
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis (1996) 3.52
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet (1985) 3.50
Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes virus infection of young adult mice. J Immunol (1970) 3.49
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med (1992) 3.13
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
A method for measurement of antibiotics in human interstitial fluid. J Infect Dis (1972) 2.99
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia. Am J Med (1990) 2.56
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2001) 2.51
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Mass mortality of harbor seals: pneumonia associated with influenza A virus. Science (1982) 2.45